Soleno Therapeutics, Inc.

NasdaqCM:SLNO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 4.03 B

Share Price

USD 79.98

Avg Daily Volume

1,307,377

Change (1 day)

0.76%

Change (1 year)

96.08%

Change (YTD)

77.93%

Soleno Therapeutics, Inc. Shareholders' Equity for the year ending December 31, 2024: USD 245.11 M

Soleno Therapeutics, Inc. Shareholders' Equity is USD 245.11 M for the year ending December 31, 2024, a 55.62% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Soleno Therapeutics, Inc. Shareholders' Equity for the year ending December 31, 2023 was USD 157.51 M.
Soleno Therapeutics, Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 17.79 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Shareholders' Equity	Cash and Short-Term Investments	Receivables	Inventory

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	115
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.